Senolytics and "zombie cells": where the evidence actually sits

The short version

• "Zombie cells" (senescent cells) are old or damaged cells that stop dividing but do not die. Having some is normal and even useful: they help prevent cancer and help wounds heal.
• The problem is build-up. With age, the body clears them more slowly, and they leak inflammatory signals into nearby tissue.
• Senolytics are compounds meant to clear these cells. In mice, the results are strong and have been repeated by several groups.
• In people, the trials are small and short. They show the compounds can lower markers of zombie cells and inflammation, but nobody has yet shown people actually feel or function better. That larger trial work is still unfunded or unfinished.
• One common combination includes dasatinib, a prescription leukaemia drug with real side effects, so it belongs under a doctor's care.
• Related approaches are worth knowing too: fasting and autophagy, NAD, MOTS-c and thymosin alpha-1, covered in plain terms below.

Educational content, not medical advice. No doses, schedules or protocols appear anywhere. Dasatinib is an approved cancer drug with a significant adverse-effect profile; its use for aging is investigational and unapproved. No senolytic is approved for any aging-related indication.

---

You have probably met the metaphor before the biology. "Zombie cells" - cells that refuse to die, accumulate with age, and poison their neighbours - is a genuinely good piece of science communication, and it is now the load-bearing element in a lot of supplement marketing. This page is about what sits underneath it.

What cellular senescence actually is

When a cell is damaged, stressed, or has divided enough times that its telomeres are exhausted, it has three options: repair, die by apoptosis, or enter senescence - a state in which it stops dividing permanently but stays alive and metabolically active.

That third option is not a malfunction. Senescence is a tumour-suppression mechanism: a cell with damaged DNA that cannot divide cannot become a cancer. It also has roles in wound healing and embryonic development. Senescent cells are supposed to exist.

The problem is what happens next. Senescent cells secrete a cocktail of inflammatory signals, growth factors and enzymes collectively called the senescence-associated secretory phenotype (SASP) - including interleukin-6, interleukin-1α, and matrix metalloproteinases. In the short term this recruits immune cells to come and clear the senescent cell away. With age, that clearance becomes less efficient, senescent cells accumulate, and the SASP shifts from a temporary local signal to a chronic, low-grade inflammatory contribution. That mechanism overlaps substantially with what we describe in inflammaging, and both connect to the broader picture in mitochondria and aging.

Senolytics are compounds intended to selectively kill senescent cells while leaving healthy ones alone. Senomorphics, a separate category, aim instead to suppress the SASP without killing the cell.

Where the "zombie cell" metaphor helps and where it misleads

It helps because it captures three real things: the cells don't divide, they don't die, and they cause trouble for their neighbours. That is a fair summary.

It misleads in three ways worth naming.

It implies senescent cells are purely pathological. They are not - they suppress tumours and assist wound healing. A hypothetical drug that removed all of them would not obviously be good for you.

It implies they are a discrete, countable population. Senescence is not a single, cleanly defined cell state with an agreed marker. Different tissues, different triggers and different markers give different answers, and there is genuine disagreement in the field about how to identify a senescent cell reliably. "How many zombie cells do you have" is not currently an answerable question.

It implies clearing them is the whole intervention. The mouse work that made this field exciting used genetically engineered systems to remove senescent cells with a precision no drug currently matches. Translating that to a compound taken by a person is where most of the difficulty lives, and the metaphor skips over all of it.

What the preclinical work established

This is the strongest part of the evidence base and it deserves credit.

In mice, selectively removing senescent cells - initially through genetic tools, later with drug combinations - improved a range of age-related measures: better physical function, improved cardiac and kidney function, reduced age-related pathology in multiple tissues, and in several studies an extension of healthspan, the period of life spent without significant disease. Senolytics also improved outcomes in mouse models of idiopathic pulmonary fibrosis, osteoarthritis and atherosclerosis.

That is a serious body of animal work, replicated across groups. It is also mouse work, and the graveyard of aging research is full of interventions that extended rodent healthspan and did nothing measurable in humans. Preclinical is preclinical - the same standard we apply everywhere in this library.

What human trials exist, and what they measured

Here is the honest tier.

Dasatinib plus quercetin (D+Q) is the most-studied combination. The landmark early human study was a phase 1 pilot in patients with diabetic kidney disease, which reported reduced senescent-cell burden in adipose tissue within about 11 days, alongside decreases in circulating SASP factors including IL-1α, IL-6 and MMP-9 and MMP-12. That study did what a phase 1 study is meant to do: it showed the mechanism can be engaged in a human being. It did not show that anyone got better.

By early 2026, roughly 14 completed human trials of D+Q had been reported, with phase 2 trials underway in idiopathic pulmonary fibrosis, Alzheimer's disease and frailty. A small trial in mild cognitive impairment has reported. Further pilots are running in older adults with serious psychiatric illness.

Fisetin, a flavonoid, outperformed quercetin and several other flavonoids in laboratory senolytic screens, which is why it appears in so much supplement marketing. Human work includes the Mayo Clinic's AFFIRM trial, with preliminary reports of reductions in circulating inflammatory markers including IL-6 and TNF-α.

Now the qualifications, which are the point of this section:

The distinction in that last row is the one that does the most work across this whole field. A biomarker moving in the right direction is a hypothesis, not a benefit. Medicine has an extensive record of interventions that moved a marker convincingly and failed to help anyone - and occasionally harmed people - when finally tested against outcomes that mattered.

The intermittent-dosing hypothesis, stated as a hypothesis

One idea that recurs in this literature: because senolytics are meant to kill cells rather than occupy a receptor, they might not need continuous exposure. Clear the accumulated senescent cells, stop, let them slowly re-accumulate, repeat later. This is sometimes called a "hit-and-run" approach.

It is a coherent hypothesis with some preclinical support, and it is not established in humans. We raise it only because it has been converted into a marketing structure - schedules built around it appear throughout the commercial senolytic category - and readers should know that the schedule is derived from a hypothesis rather than from human outcome data. We do not publish schedules or dosing for any compound, and this one has less human grounding than most.

A related caution belongs here. Dasatinib is a prescription tyrosine kinase inhibitor approved for leukaemia. It has a substantial adverse-effect profile including cytopenias, fluid retention and pleural effusion, and it is used in oncology under close monitoring. Its appearance in longevity discussions alongside a supplement-aisle flavonoid can obscure that it is a serious cancer drug. Any use outside its approved indication is investigational and belongs.

What would have to be true for the category to earn a stronger claim

Concretely:

1. Randomised, blinded, adequately powered trials in the populations actually being marketed to - that is, people who are aging normally, not only patients with a specific disease.
2. Clinical endpoints, not surrogates. Physical function, incidence of age-related disease, disability-free survival. Not IL-6.
3. A validated way to measure senescent-cell burden in a living person, so that "it cleared senescent cells" is a measurable claim rather than an inference.
4. Long-term safety data, particularly given that senescence is a tumour-suppression mechanism and these compounds interfere with it. The theoretical cancer-risk question is not settled and cannot be settled by short trials.
5. Replication by independent groups, including groups without a commercial position.

None of that is unreasonable. Some of it is in progress. Until a meaningful amount of it exists, "senolytics slow human aging" is a claim ahead of its evidence, however good the underlying biology looks.

Related approaches: fasting, NAD, MOTS-c and thymosin alpha-1

Senolytics are not the only idea aimed at the same problem. These come up often alongside them. None of them is a senolytic, and none has been shown to clear zombie cells in people, but each touches the same biology.

• Intermittent fasting and autophagy. Autophagy is the cell's clean-up and recycling system. In animal studies, fasting and eating less switch it on strongly, and that is one reason fasting is so popular in longevity circles. Whether intermittent fasting reduces senescent cells in people has not been established. Our guide to autophagy and spermidine explains how fasting, autophagy and "fasting-mimic" compounds fit together.
• NAD and NMN. NAD is a molecule every cell needs to make energy and repair DNA, and levels tend to fall with age. Some researchers think senescent cells and the inflammation they cause help drain NAD. Supplements such as NMN and NR raise NAD levels in blood, but whether that slows ageing in people is still unproven. See does NAD decline with age? and NAD vs NMN vs NR. Vivre Labs offers NAD+.
• MOTS-c. A small peptide made by mitochondria. In older mice, it improved physical capacity, and it is being studied as an "exercise mimetic" (something that copies some of exercise's signals). It does not target zombie cells, has no completed human trial and is investigational. More in MOTS-c, the exercise mimetic.
• Thymosin alpha-1. Part of why zombie cells build up is that the immune system, which normally clears them, weakens with age. Thymosin alpha-1 is a peptide originally found in the thymus gland that helps train T cells (immune cells that direct attacks). It is approved in some countries for certain infections and as a vaccine helper, and is investigational in the US. No study has shown that it clears senescent cells. See our thymosin alpha-1 guide.

If you want to explore any of these, start with a baseline. Our what to test panel covers inflammation and metabolic markers, so you can measure change rather than guess. Our cellular energy and longevity protocol brings MOTS-c, SS-31 and epithalon together.

Frequently asked questions

Do senolytics work in humans? They appear to do something measurable: early trials report reduced senescent-cell markers and lower inflammatory signals in specific patient groups. Whether that translates into people being healthier, functioning better, or living longer has not been demonstrated. The honest answer is that the mechanism engages and the benefit is unproven.

Is fisetin a proven senolytic? Fisetin performs well in laboratory senolytic screens - better than several comparable flavonoids - and human trials including Mayo's AFFIRM programme have reported reductions in circulating inflammatory markers. That is early-stage evidence on surrogate endpoints. It is not a demonstration of clinical benefit, and laboratory potency does not reliably predict effects in a person.

What is the difference between a senolytic and a senomorphic? A senolytic aims to selectively kill senescent cells. A senomorphic aims to leave them alive but suppress the inflammatory signals they secrete. Different strategies, different risk profiles, and the evidence for both is early.

Are senescent cells simply bad? No, and this is the most common misunderstanding. Senescence suppresses tumour formation and contributes to wound healing. The problem is accumulation and chronic SASP signalling with age, not the existence of senescent cells. That is part of why indiscriminate clearance is not obviously desirable and why long-term safety data matter.

Should I take a senolytic supplement? That is a question for a clinician who knows your history, and our answer as a matter of policy is that we do not recommend, rank or endorse products in this category. The evidence does not currently support a confident recommendation in either direction for healthy people, and one commonly discussed senolytic combination includes a prescription cancer drug.

---

Where Vivre stands

Senolytics are among the most mechanistically credible ideas in longevity biology and among the most aggressively marketed. Those two facts are not in tension - the credibility is exactly what makes the marketing possible.

Our position is the same one we apply to every compound here: preclinical results are preclinical, biomarker changes are hypotheses, and a compelling mechanism is a reason to run trials rather than a reason to act. If the phase 2 programmes in fibrosis, frailty and cognition report well, this becomes a genuinely important story. They have not reported yet.

If you are interested in this category because you want to understand your own aging trajectory, the more useful step is measurement - establishing where your inflammatory and metabolic markers actually sit - rather than adding a compound whose human evidence stops at markers.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial.

Related reading

• Autophagy and spermidine · Does NAD decline with age? · NAD vs NMN vs NR · MOTS-c · Thymosin alpha-1 · Mitophagy and urolithin A · Mitochondria and aging · Inflammaging · Does rapamycin slow aging in humans?
• Part of Mitochondria & Cellular Energy

---

Educational content, not medical advice. No senolytic compound is approved for any aging-related indication. Dasatinib is a prescription oncology drug with a significant adverse-effect profile; any non-oncology use is investigational and belongs under medical supervision. No doses, schedules or protocols appear here. Claims for the Malaysian market are subject to MAB requirements.

References

• Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796530/ - reduced adipose senescent-cell burden within ~11 days; decreases in circulating IL-1α, IL-6, MMP-9 and MMP-12. Phase 1, small, surrogate endpoints.
• Protocol for a pilot clinical trial of dasatinib plus quercetin in older adults with serious mental illness. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120425/ · PubMed: https://pubmed.ncbi.nlm.nih.gov/40443429/
• Trial-landscape summary as of early 2026: approximately 14 completed human D+Q trials; phase 2 programmes in idiopathic pulmonary fibrosis, Alzheimer's disease and frailty.
• Small trial of dasatinib and quercetin in mild cognitive impairment (2025), summary reporting: https://www.fightaging.org/archives/2025/03/results-from-a-small-trial-of-dasatinib-and-quercetin-in-patients-with-mild-cognitive-impairment/
• Fisetin: comparative senolytic screening against quercetin, curcumin, luteolin and other flavonoids; Mayo Clinic AFFIRM trial (Acute Effects of Fisetin In Reducing inflammation and related Markers), preliminary reports of reduced circulating IL-6 and TNF-α.
• Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. Mouse study.
• Cellular senescence and the senescence-associated secretory phenotype: standard review literature. Senescence functions in tumour suppression and wound healing as well as in age-related pathology.